Literature DB >> 12225358

Bugs as drugs for cancer.

Eleanor J Cheadle1, Andrew M Jackson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12225358      PMCID： PMC1782780          DOI： 10.1046/j.1365-2567.2002.01498.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  89 in total

1.  Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes.

Authors:  N S Potter; C V Harding
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

2.  The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

Authors:  M von Mehren; P Arlen; J Gulley; A Rogatko; H S Cooper; N J Meropol; R K Alpaugh; M Davey; S McLaughlin; M T Beard; K Y Tsang; J Schlom; L M Weiner
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity.

Authors:  Björn Cochlovius; Marike J J G Stassar; Marco W Schreurs; Axel Benner; Gosse J Adema
Journal:  Immunol Lett       Date:  2002-02-01       Impact factor: 3.685

4.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

5.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

6.  Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins.

Authors:  I A Jabbar; G J Fernando; N Saunders; A Aldovini; R Young; K Malcolm; I H Frazer
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

7.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

8.  Analysis of p53 in human cutaneous melanoma cell lines.

Authors:  X Montano; M Shamsher; P Whitehead; K Dawson; J Newton
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

9.  Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.

Authors:  C F Hung; W F Cheng; K F Hsu; C Y Chai; L He; M Ling; T C Wu
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 13.312

10.  Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.

Authors:  R Mendes; M E R O'Brien; A Mitra; A Norton; R K Gregory; A R Padhani; K V Bromelow; A R Winkley; S Ashley; I E Smith; B E Souberbielle
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640
View more
  7 in total

1.  Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells.

Authors:  Eleanor J Cheadle; Dearbhaile O'Donnell; Peter J Selby; Andrew M Jackson
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 2.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

3.  TLR3 agonists and proinflammatory antitumor activities.

Authors:  Sherven Sharma; Li Zhu; Michael Davoodi; Marni Harris-White; Jay M Lee; Maie St John; Ravi Salgia; Steven Dubinett
Journal:  Expert Opin Ther Targets       Date:  2013-03-19       Impact factor: 6.902

Review 4.  The application of Toll like receptors for cancer therapy.

Authors:  Eui Young So; Toru Ouchi
Journal:  Int J Biol Sci       Date:  2010-11-03       Impact factor: 6.580

Review 5.  Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?

Authors:  S D Killeen; J H Wang; E J Andrews; H P Redmond
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640

6.  Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.

Authors:  M Gabriela Kramer; Martín Masner; Erkuden Casales; María Moreno; Cristian Smerdou; José A Chabalgoity
Journal:  BMC Cancer       Date:  2015-09-07       Impact factor: 4.430

7.  Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.

Authors:  M Gabriela Kramer; Martín Masner; Fernando A Ferreira; Robert M Hoffman
Journal:  Front Microbiol       Date:  2018-01-23       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.